A critical evaluation of the European drug strategy: Has it brought added value to drug policy making at the national level?

It finds that neither the Commission's dedication to increasing focus on law-enforcement methods, nor the Council's prescription for 'more of the same' are particularly beneficial to the development of European drug policy. Instead, the priorities should be building on areas where added value has been engendered and on allowing diversity in policy to flourish.